You searched for marketing - Page 4 of 26

Weekly reads: oocytes from males, David Sinclair longevity inc, diabetes, He Jiankui

March 19, 2023 March 18, 2023 / By Professor Paul Knoepfler, Ph.D. / Leave a Comment

A team led by Harvard professor David Sinclair had a recent Cell paper on reprogramming to fight aging that I reviewed here on The Niche. I thought the paper was exciting and important. Note that in vivo reprogramming was first done more than a decade ago. Sinclair did have a novel fast-forward aging method and overall …

Weekly reads: oocytes from males, David Sinclair longevity inc, diabetes, He Jiankui Read More »

Where Kimera Labs fits into sphere of exosome companies

March 16, 2023 March 16, 2023 / By Professor Paul Knoepfler, Ph.D. / 4 Comments

Today’s post takes a close look at the exosome manufacturer Kimera Labs in the context of the main exosome companies. What are exosomes? Exosomes are microscopic bubbles or vesicles produced by cells. Exosomes contain many cellular substances that are biologically active. Some of these materials may be helpful clinically, while others could pose risks. Clinical outcomes …

Where Kimera Labs fits into sphere of exosome companies Read More »

WHYY oh WHYY: NPR puff piece on risky stem cell microneedling

March 14, 2023 March 24, 2023 / By Professor Paul Knoepfler, Ph.D. / 2 Comments

I usually associate NPR with solid journalism so I was scratching my head about a recent puff piece by WHYY on stem cell microneedling. Is this journalism or product promotion? The NPR piece by Maiken Scott doesn’t ask important questions. Scott received stem cell microneedling herself using a product from a company called AnteAGE. How …

WHYY oh WHYY: NPR puff piece on risky stem cell microneedling Read More »

LifeWave X39 stem cell patch story has holes

February 14, 2023 October 9, 2023 / By Professor Paul Knoepfler, Ph.D. / 253 Comments

I often learn about new supposedly stem cell-related products like the LifeWave X39 Patch from readers. Sometimes such products are used by tens of thousands of people, in my view potentially raising risks to the public. If nothing else, people might be spending their money on something that isn’t worth it. As a stem cell biologist, …

LifeWave X39 stem cell patch story has holes Read More »

Are immortal jellyfish actually mortal?

January 24, 2023 January 23, 2023 / By Professor Paul Knoepfler, Ph.D. / 1 Comment

About ten years ago I ran across the organism called the immortal jellyfish. Luckily I didn’t get stung because it wasn’t an in-person encounter like while swimming. Rather, I came upon the idea that these guys lived forever. Someone was even selling an immortal jellyfish extract. They claimed it would reverse aging in people. That …

Are immortal jellyfish actually mortal? Read More »

Does Medicare cover stem cell therapy? Mostly no & it’s poised to recoup tens of millions

January 19, 2023 January 19, 2023 / By Professor Paul Knoepfler, Ph.D. / 2 Comments

Regenative labs, does Medicare cover stem cell therapy?

Does Medicare cover stem cell therapy? Readers of The Niche have regularly asked this question. They’re curious about insurance coverage too. The answer is “no” in almost every case, with some notable exceptions I’ll get to at the end of the post. Still, clinics appear to have already been charging Medicare for what collectively adds …

Does Medicare cover stem cell therapy? Mostly no & it’s poised to recoup tens of millions Read More »

Desperately seeking stem cells: celeb quests for elixirs often mislead

January 10, 2023 January 9, 2023 / By Professor Paul Knoepfler, Ph.D. / 3 Comments

What could go wrong with celebrities desperately hunting for stem cells as a fountain of youth? A flaskful of problems. Some famous folks can’t seem to get enough of stem cells, even if those supposed therapies are unproven and risky. In recent years, dozens of celebs have gotten stem cell procedures of various kinds. The …

Desperately seeking stem cells: celeb quests for elixirs often mislead Read More »

3rd Invitrx warning highlights FDA oversight weakness

January 4, 2023 January 4, 2023 / By Professor Paul Knoepfler, Ph.D. / 8 Comments

The FDA seems oddly slow in oversight of unproven stem cell clinic-related firms like one here in California called Invitrx Therapeutics. I’ve written before about Invitrx, but interactions between them and the FDA have continued including a new warning letter. It’s become a puzzling situation. More broadly, the FDA has done relatively little in the past …

3rd Invitrx warning highlights FDA oversight weakness Read More »

Fact-checking stem cell stroke therapy: hope but not there yet

December 13, 2022 December 13, 2022 / By Professor Paul Knoepfler, Ph.D. / 9 Comments

Stem cell stroke therapy research has generated buzz over the years. The goal of today’s post is to fact-check claims about supposed stem cell stroke therapies and educate readers on where clinical research stands. There is some real hope here in the long run, but things have been greatly exaggerated at times. Some clinics are …

Fact-checking stem cell stroke therapy: hope but not there yet Read More »

What are senolytics? Drugs, activator, supplements, risks

October 4, 2022 October 3, 2022 / By Professor Paul Knoepfler, Ph.D. / 1 Comment

As we age a higher proportion of our cells end up in a senescent state, which has sparked interest in senolytic drugs and a broader area called senolytics research. The goal of today’s post is to give you an overview of this important area. How much data are there on efficacy or safety? Is the …

What are senolytics? Drugs, activator, supplements, risks Read More »

Search Results for: marketing